Pierluigi Porcu
Dr. Porcu is the Ewa Marciniak, MD, Endowed Chair Professor and Division Chief for Hematology and Cellular Therapy at the University of Kentucky College of Medicine, and Associate Director for Clinical Translation at the UK Lucille P. Markey Comprehensive Cancer Center. Dr Porcu is an NCI-funded physician scientist and an internationally recognized expert in clinical and translational research in T-cell lymphoma. He is a former President of the United State Cutaneous Lymphoma Consortium (USCLC), and a member of the board of directors of the International Society of Cutaneous Lymphomas (ISCL). Dr. Porcu has served as global coordinating investigator or chair on numerous advisory boards and clinical trial steering committees and is the former Chair of the Cutaneous Lymphoma Foundation (CLF) research advisory board.
Dr. Porcu earned his medical degree from the University of Torino in Italy and completed a residency in internal medicine and a fellowship in hematology-oncology at Indiana University in Indianapolis. From 1999 to 2015 he was a faculty in the Division of Hematology at The Ohio State University. From 2016 to 2025 he served as Professor and Division director of Hematologic malignancies and hematopoietic stem cell transplantation in the Department of Medical Oncology at Thomas Jefferson University in Philadelphia. He was also the leader of the immune cell regulation and targeting (IRT) program of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) and co-leader of the SKCCC’s Blood Cancer Center of Excellence (BCCE). As division director at TJU, Dr. Porcu was at the forefront of a period of explosive growth and of unprecedented research integration within Jefferson Health’s large matrixed health enterprise. He has been continuously listed among U.S. News & World Report’s Top Cancer Doctors in America, Newsweek’s Top Hematology Doctors, and has been named to Philadelphia magazine’s Top Doctors list since 2016.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Innate PharmaTopic:Clinical TrialDate added:01/08/2026Date updated:01/08/2026
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ArtivaTopic:Clinical TrialDate added:01/08/2026Date updated:01/08/2026

Facebook
X
LinkedIn
Forward